Recent Analyst Stock Rating News
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.Guggenheim Analyst
Eddie Hickman is an analyst at Guggenheim. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 12/15/2025
| Buy Now | Get Alert | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 12/03/2025 | CYBN | Buy Now | Cybin | — | — | $39 → $48 | Maintains | Buy | Get Alert | |
| 11/18/2025 | PMN | Buy Now | ProMIS Neurosciences | $9.25 | -45.95% | $6 → $5 | Maintains | Buy | Get Alert | |
| 11/05/2025 | TARS | Buy Now | Tarsus Pharmaceuticals | $80.48 | 8.1% | $84 → $87 | Maintains | Buy | Get Alert | |
| 08/29/2025 | OTLK | Buy Now | Outlook Therapeutics | $2.21 | — | — | Downgrade | Buy → Neutral | Get Alert | |
| 05/02/2025 | TARS | Buy Now | Tarsus Pharmaceuticals | $80.48 | 4.37% | $78 → $84 | Maintains | Buy | Get Alert | |
| 04/01/2025 | PMN | Buy Now | ProMIS Neurosciences | $9.25 | -35.14% | $6 → $6 | Reiterates | Buy → Buy | Get Alert | |
| 03/13/2025 | ZVRA | Buy Now | Zevra Therapeutics | $8.15 | 169.91% | $20 → $22 | Maintains | Buy | Get Alert | |
| 03/13/2025 | GHRS | Buy Now | GH Research | $12.48 | 156.31% | → $32 | Initiates | → Buy | Get Alert | |
| 03/13/2025 | CYBN | Buy Now | Cybin | — | — | → $35 | Initiates | → Buy | Get Alert | |
| 02/26/2025 | PMN | Buy Now | ProMIS Neurosciences | $9.25 | — | — | Reiterates | Buy → Buy | Get Alert | |
| 02/26/2025 | TARS | Buy Now | Tarsus Pharmaceuticals | $80.48 | -3.08% | $75 → $78 | Maintains | Buy | Get Alert | |
| 02/24/2025 | TARS | Buy Now | Tarsus Pharmaceuticals | $80.48 | — | — | Reiterates | Buy → Buy | Get Alert | |
| 02/10/2025 | TARS | Buy Now | Tarsus Pharmaceuticals | $80.48 | — | — | Reiterates | Buy → Buy | Get Alert | |
| 01/17/2025 | OTLK | Buy Now | Outlook Therapeutics | $2.21 | 442.99% | $12 → $12 | Reiterates | Buy → Buy | Get Alert | |
| 01/25/2024 | OTLK | Buy Now | Outlook Therapeutics | $2.21 | -9.5% | → $2 | Upgrade | Neutral → Buy | Get Alert | |
| 09/11/2023 | TARS | Buy Now | Tarsus Pharmaceuticals | $80.48 | -39.12% | $46 → $49 | Maintains | Buy | Get Alert | |
| 08/14/2023 | TARS | Buy Now | Tarsus Pharmaceuticals | $80.48 | -42.84% | → $46 | Reiterates | Buy → Buy | Get Alert | |
| 06/16/2023 | TARS | Buy Now | Tarsus Pharmaceuticals | $80.48 | -47.81% | $40 → $42 | Maintains | Buy | Get Alert | |
| 05/18/2023 | TARS | Buy Now | Tarsus Pharmaceuticals | $80.48 | — | — | Initiates | → Buy | Get Alert | |
| 05/01/2023 | ISEE | Buy Now | IVERIC bio | — | — | — | Downgrade | Buy → Neutral | Get Alert | |
| 04/03/2023 | OTLK | Buy Now | Outlook Therapeutics | $2.21 | 126.24% | → $5 | Initiates | → Buy | Get Alert | |
| 09/07/2022 | ISEE | Buy Now | IVERIC bio | — | — | $30 → $35 | Maintains | Buy | Get Alert |
A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.